Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
UroGen Pharma Ltd.
URGN · SEC Filings
website
300
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of sol...
Price
26.31
Market Cap
1.29 B
Float
43.56 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about URGN
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
UroGen Pharma Ltd.
URGN · SEC Filings
43.56 M
Float
26.31
Price
1.29 B
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 4, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 6, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 2, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 7, 2025
News
TYPE
HEADLINE
FILED AT
8-K
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Nov 4, 2026
8-K
UroGen Pharma Enters Option and Research License Agreement with IntraGel Therapeutics
Aug 20, 2026
8-K
UroGen Reports $50.4 Million in ZUSDURI Revenue and Q2 2026 Financial Results
Aug 5, 2026
8-K
UroGen Pharma Ltd. Announces Results of 2026 Annual Meeting of Shareholders
Jun 23, 2026
8-K
UroGen Pharma Settles Patent Litigation with Teva Regarding Jelmyto®
Jun 2, 2026
8-K
UroGen Reports Q1 2026 Financial Results and Significant ZUSDURI Revenue Growth
May 6, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
5,000,000 Ordinary Shares
Jun 18, 2024
424B5
$250,000,000
Jun 17, 2024
424B5
Up to $83,375,000 Ordinary Shares PROSPECTUS Cowen November 29, 2022
Dec 1, 2022
424B5
Up to $100,000,000 Ordinary Shares PROSPECTUS Cowen January 2, 2020
Jan 2, 2020
424B5
3,658,537 Ordinary Shares
Jan 25, 2019
424B5
$150,000,000
Jan 22, 2019
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 4, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 6, 2025
S-3ASR
November 2025 SHELF & ATM
Nov 6, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Aug 13, 2024
S-8
Registration
Nov 14, 2023
S-3
12,579,156 Ordinary Shares EFFECTIVE
Sep 8, 2023
Proxies
TYPE
HEADLINE
FILED AT
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
BlackRock, Inc. (Filed by)
Oct 27, 2026
4
Degnan Chris (Reporting)
Oct 9, 2026
144
Form 144 - Report of proposed sale of securities
Oct 9, 2026
4
Schoenberg Mark (Reporting)
Sep 9, 2026
4
Smith Jason Drew (Reporting)
Sep 9, 2026
144
Form 144 - Report of proposed sale of securities
Sep 9, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
LETTER
Form UPLOAD - SEC-generated letter
Dec 5, 2023
CORRESP
Form CORRESP - Correspondence
Nov 27, 2023
LETTER
Form UPLOAD - SEC-generated letter
Nov 16, 2023
EFFECT
Form EFFECT - Notice of Effectiveness
Sep 18, 2023
CORRESP
Form CORRESP - Correspondence
Sep 13, 2023
LETTER
Form UPLOAD - SEC-generated letter
Sep 12, 2023
